
DukeNUS Medical School | National Cancer Centre Singapore SingHealth | CSCB Cancer and Stem Cell Biology Seminar Series

Targeting specific genomic vulnerabilities in solid tumors.

Abstract:

The presence of oncogenic genomic alterations propels tumor formation and progression. Moreover, the acquisition of specific aberrations during tumor evolution renders these tumors less prone to respond to chemotherapy and targeted therapy. On the other hand, these alterations can also offer the opportunity to test the activity of novel (and not always obvious) therapeutic options that specifically target these new vulnerabilities. In this work, we show examples where the presence of specific gene mutations provides an opportunity for rationale-based therapeutic combinations that act via novel mechanisms of action. Importantly, many of these combinatorial therapies are based on FDA-approved drugs currently used as standard of care in solid tumors. The presence of oncogenic genomic alterations propels tumor formation and progression. Moreover, the acquisition of specific aberrations during tumor evolution renders these tumors less prone to respond to chemotherapy and targeted therapy. In this work, however, we show specific cases where the presence of specific gene mutations provides an opportunity for therapeutic combinations that act via novel (and not always obvious) mechanisms of action.

Speaker:



Maurizio Scaltriti, Ph.D.

Principal investigator
Memorial Sloan Kettering Cancer Center
New York

Maurizio Scaltriti, PhD, is an Associate Laboratory Member in the Human Oncology & Pathogenesis Program at Memorial Sloan Kettering Cancer Center. He received his PhD at the University of Modena in Italy, and completed his postdoctoral fellowship at the Vall d'Hebron University Hospital in Barcelona, Spain. Dr. Scaltriti's research focuses on identifying mechanisms that limit the sensitivity to targeted therapy in solid tumors, in particular to PI3K/Akt/mTOR inhibitors and anti-HER2 agents. His work aims to provide insights into designing more effective clinical trials that test novel therapeutic combinations in precise subsets of cancer patient populations.

Date:

21 January 2019 (Tuesday)

Venue:

Meeting Room 7C, Level 7
Duke-NUS Medical School
8, College Road,
Singapore 169857

Time:

12:00 - 1:00 p.m.

Host:

Prof Kanaga Sabapathy
Deputy Director
Cancer & Stem Cell Biology
Duke-NUS Medical School

Head and Principal Investigator
Division of Cellular & Molecular Research
National Cancer Centre Singapore

No registration is required.
All are welcome.

Any enquiries, please contact:
Jamie Liew (+65 6516 6954)